If you experience significant gastrointestinal adverse effects, your doctor may recommend pausing or reducing the dose
GLP-1 Analogue Improves Hepatic Lipid Accumulation by Inducing Autophagy via AMPK/mTOR Pathway
It is possible that prescriptions were not filled or that patients were not compliant with prescribed dosing frequencies
FDA has approved an expanded indication for Wegovy (semaglutide 2.4 mg) in adults with noncirrhotic MASH (F2F3), alongside diet and exercise
If symptoms suggest a new endocrine problem, baseline testing is reasonable before starting therapy, with a follow-up check at three months for the standard panels: HbA1c, fasting glucose, TSH, and free T4 if on thyroid therapy, morning cortisol only when clinically indicated, and sex hormones if symptoms arise